Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: orally available BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms
Date Designated: 12/18/2024
Orphan Designation: treatment of Waldenstrom macroglobulinemia
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
BeOne Medicines USA, Inc.
311 Pennington-Rocky Hill Rd., Bldg 51-Ste 1358
Pennington, New Jersey 08534
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-